# Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions - Link: https://www.thailand-business-news.com/pr-news/innovent-to-present-multiple-clinical-and-preclinical-results-of-mazdutide-and-next-generation-obesity-metabolic-pipeline-at-the-2026-ada-scientific-sessions - Published: 2026-05-13T07:00:00+07:00 - Author: PR Newswire SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from mazdutide and its next‑generation obesity and metabolic pipeline at the 2026 American Diabetes Association’s^(® )(ADA) Scientific Sessions, to be held in New Orleans, U.S. from June 5–8, 2026. **Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent,** stated, " At this year’s ADA Scientific Sessions, we are pleased to present a series of new data in obesity and metabolic diseases, which is an important step in establishing Innovent as an emerging leader and innovator in this field. The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032(oral daily GLP-1 small molecule), IBI3042( oral weekly GLP-1 small molecule), IBI3040(amylin) and IBI3046(INHBE siRNA) represent key milestones of our next‑generation obesity pipeline with global potential, which are designed to address unmet needs around tolerability, muscle preservation, dosing convenience, durability of weight loss and management of obesity‑related comorbidities." Abstracts Summary at ADA 2026: **Mazdutide Oral Presentations** 1. **Title: Mazdutide versus Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomized, Open-Label Phase 3b Clinical Trial** Abstract No.: 1226-ORTime: 8:15 AM – 8:30 AM, Sunday, June 7, 2026 (Central Time, U.S.)Presenter: Professor Linong Ji, Peking University People’s Hospital 2.** Title: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Clinical Trial** Abstract No.: 1225-ORTime: 8:00 AM – 8:15 AM, Sunday, June 7, 2026 (Central Time, U.S.)Presenter: Dr. Leili Gao, Peking University People’s Hospital 3. **Title: Safety, Tolerability and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Clinical Trial** Abstract No.: 1133- ORTime: 5:30 PM – 5:45 PM, Friday, June 5, 2026 (Central Time, U.S.)Presenter: Professor Chunxiu Gong, Beijing Children’s Hospital, Capital Medical University These three studies together cover type 2 diabetes with obesity, adult with obesity and adolescent obesity, and will comprehensively demonstrate the clinical value of mazdutide in weight management, glycemic control and metabolic improvement, further strengthening its differentiated positioning as a next‑generation GCG/GLP‑1 dual receptor agonist in the obesity and metabolic disease areas. **Mazdutide Poster Presentations** 4. **Title: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk\*Abstract Number: 2505-P Date& Time: Sunday, June 7, 2026, 12:30-1:30 PM (Central Time, USA)Presenter: Dr. Lingfeng Zhang, China Pharmaceutical University 5. **Title: Dual GLP-1R/GCGR Activation Reprograms Systemic and Hepatic Metabolism to Ameliorate MAFLD\*Abstract Number: 1686-P Date & Time: Sunday, June 7, 2026, 12:30-1:30 PM (Central Time, USA)Presenter: Dr. Danni Gao, Beijing Hospital _*Abstracts 2505-P & 1686-P are from investigator-initiated clinical trials (IIT)._ **Next-gen Innovative Pipeline Poster Presentations** 1.** Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese AdultsAbstract No.: 1690-P Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)Presenter: Dr. Huan Deng, Innovent Biologics 2. **Title: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing Through Phase 1 Clinical TrialsAbstract No.: 1678-P Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)Presenter: Dr. Decheng Ren, Innovent Biologics 3. **Title: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical ModelsAbstract No.: 3077-LB Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)Presenter: Dr. Yuqiang Niu, Innovent Biologics 4. **Title: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity** Abstract No.: 2543-PTime: 12:30 PM – 1:30 PM, Monday, June 8, 2026 (Central Time, U.S.)Presenter: Dr. Decheng Ren, Innovent Biologics 5. **Title: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical StudyAbstract No.: 2662-P Time: 12:30 PM – 1:30 PM, Monday, June 8, 2026 (Central Time, U.S.)Presenter: Dr. Xiguang Zhang, Innovent Biologics Taken together, IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑ 1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA), form a layered and differentiated innovation portfolio for Innovent in the global obesity and metabolic comorbidity space. These programs are designed to address key global obesity challenges, including improving tolerability, reducing muscle loss, extending dosing intervals, maintaining durable weight loss, and comprehensively managing obesity‑related comorbidities. **About Innovent** Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit [www.innoventbio.com](http://www.innoventbio.com/), or follow Innovent on Facebook and LinkedIn. **Forward-looking statement** This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", " believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward- looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and ( b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. --- | This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. | --- **Read the original article :** [Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions ](http://www.prnasia.com/story/archive/4957404_CN57404_0?rand=184833)